These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 19716455)

  • 21. Finding a Toll on the Route: The Fate of Osteoclast Progenitors After Toll-Like Receptor Activation.
    Souza PPC; Lerner UH
    Front Immunol; 2019; 10():1663. PubMed ID: 31379855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
    Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
    Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
    Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteoclast differentiation by RANKL and OPG signaling pathways.
    Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
    J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDH2 deficiency increases bone mass with reduced osteoclastogenesis by limiting RANKL expression in osteoblasts.
    Lee SH; Lee SH; Lee JH; Park JW; Kim JE
    Bone; 2019 Dec; 129():115056. PubMed ID: 31479775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCL20 chemokine induces both osteoblast proliferation and osteoclast differentiation: Increased levels of CCL20 are expressed in subchondral bone tissue of rheumatoid arthritis patients.
    Lisignoli G; Piacentini A; Cristino S; Grassi F; Cavallo C; Cattini L; Tonnarelli B; Manferdini C; Facchini A
    J Cell Physiol; 2007 Mar; 210(3):798-806. PubMed ID: 17133360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
    Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
    J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association.
    Martin A; Xiong J; Koromila T; Ji JS; Chang S; Song YS; Miller JL; Han CY; Kostenuik P; Krum SA; Chimge NO; Gabet Y; Frenkel B
    Bone; 2015 Jun; 75():96-104. PubMed ID: 25701138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.
    Song I; Kim JH; Kim K; Jin HM; Youn BU; Kim N
    FEBS Lett; 2009 Jul; 583(14):2435-40. PubMed ID: 19576893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PKC-δ deficiency in B cells displays osteopenia accompanied with upregulation of RANKL expression and osteoclast-osteoblast uncoupling.
    Li S; Liu Q; Wu D; He T; Yuan J; Qiu H; Tickner J; Zheng SG; Li X; Xu J; Rong L
    Cell Death Dis; 2020 Sep; 11(9):762. PubMed ID: 32938907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
    Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
    Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss.
    Yu W; Zhong L; Yao L; Wei Y; Gui T; Li Z; Kim H; Holdreith N; Jiang X; Tong W; Dyment N; Liu XS; Yang S; Choi Y; Ahn J; Qin L
    J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33206630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).
    Ang ES; Zhang P; Steer JH; Tan JW; Yip K; Zheng MH; Joyce DA; Xu J
    J Cell Physiol; 2007 Sep; 212(3):787-95. PubMed ID: 17477372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coupling of bone resorption and formation by RANKL reverse signalling.
    Ikebuchi Y; Aoki S; Honma M; Hayashi M; Sugamori Y; Khan M; Kariya Y; Kato G; Tabata Y; Penninger JM; Udagawa N; Aoki K; Suzuki H
    Nature; 2018 Sep; 561(7722):195-200. PubMed ID: 30185903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GATA4 represses RANKL in osteoblasts via multiple long-range enhancers to regulate osteoclast differentiation.
    Khalid AB; Slayden AV; Kumpati J; Perry CD; Berryhill SB; Crawford JA; Fatima I; Morselli M; Pellegrini M; Miranda-Carboni GA; Krum SA
    Bone; 2018 Nov; 116():78-86. PubMed ID: 30031905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
    Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
    Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts.
    Hikata T; Takaishi H; Takito J; Hakozaki A; Furukawa M; Uchikawa S; Kimura T; Okada Y; Matsumoto M; Yoshimura A; Nishimura R; Reddy SV; Asahara H; Toyama Y
    Blood; 2009 Mar; 113(10):2202-12. PubMed ID: 18952894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
    Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
    PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.